Navigation Links
New Executive Vice President Commercial Appointed
Date:5/15/2012

STOCKHOLM, May 15, 2012 /PRNewswire/ --

Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed Henric Juserius to be the new head of the company's commercial activities. Henric, who will have overall responsibility for Medivir's pharmaceutical marketing and sales, will join the company in August 2012 and will be part of the management team.

Henric Juserius has a degree in business administration and most recently held the position as Commercial Director for the Nordic region at Actelion Pharmaceuticals. He has an extensive experience from the industry and has worked with pharmaceutical marketing and sales for more than 20 years in companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

"I am very pleased to welcome Henric Juserius to Medivir as Executive Vice President, Commercial. His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435. Henric will also work on the development of Medivir's existing portfolio of prescription drugs," says Maris Hartmanis, President and CEO of Medivir.


About Medivir

Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information on Medivir, please see the company's website:  http://www.medivir.com

 

For more information, please contact

Rein Piir, EVP Corporate Affairs & IR, Office line +46-8-440-6550 or Mobile +46-708-537292, Maris Hartmanis, CEO, +46-8-407-64-30


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Evalve Expands Executive Leadership Team
6. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
7. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
8. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
9. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
10. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
11. Curemark Announces Senior Executive Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):